Compare EDBL & VRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EDBL | VRAX |
|---|---|---|
| Founded | 2020 | 2013 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8M | 1.5M |
| IPO Year | 2021 | 2021 |
| Metric | EDBL | VRAX |
|---|---|---|
| Price | $0.89 | $1.40 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 288.6K | 153.4K |
| Earning Date | 11-13-2026 | 11-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $12,810,000.00 | N/A |
| Revenue This Year | $24.00 | N/A |
| Revenue Next Year | $282.47 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.08 | $0.10 |
| 52 Week High | $18.90 | $13.19 |
| Indicator | EDBL | VRAX |
|---|---|---|
| Relative Strength Index (RSI) | 21.42 | 25.88 |
| Support Level | $0.88 | $0.16 |
| Resistance Level | $1.20 | $3.01 |
| Average True Range (ATR) | 0.06 | 0.29 |
| MACD | -0.01 | -0.05 |
| Stochastic Oscillator | 3.33 | 6.97 |
Edible Garden AG Inc is a next-generation controlled environment agriculture farming company. It uses traditional agricultural growing techniques together with technology to grow fresh, organic food, sustainably and safely while improving traceability. The company uses the controlled environment of traditional greenhouse structures, such as glass greenhouses together with hydroponic and vertical greenhouses to sustainably grow organic herbs and lettuces. Company provides two principal product segments: (i) fresh produce, including cut herbs, hydroponic basil, potted herbs, and wheatgrass; and (ii) shelf-stable and refrigerated consumer packaged goods, including sports nutrition and nutraceuticals.
Virax Biolabs Group Ltd is a biotechnology company focused on the detection of immune responses and the development of immune profiling and in vitro diagnostic technologies for viral and immune-mediated diseases, with a current strategic focus on post-acute infection syndromes (PAIS) and related areas of chronic immune dysfunction. The company's principal development activities are centered on T cell-based in vitro diagnostics and immune profiling. The company's flagship product candidate, ViraxImmune, is an in-development T cell-based assay and immune profiling platform intended to support the assessment of immune dysfunction, initially in PAIS indications.